Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$3.26 - $4.66 $117,663 - $168,193
-36,093 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$4.08 - $5.66 $7,686 - $10,663
-1,884 Reduced 4.96%
36,093 $161,000
Q2 2021

Aug 10, 2021

BUY
$5.01 - $7.48 $61,142 - $91,285
12,204 Added 47.35%
37,977 $207,000
Q1 2021

May 17, 2021

BUY
$7.19 - $14.95 $3,235 - $6,727
450 Added 1.78%
25,773 $193,000
Q4 2020

Feb 12, 2021

SELL
$6.66 - $14.66 $63,349 - $139,445
-9,512 Reduced 27.31%
25,323 $275,000
Q3 2020

Nov 13, 2020

SELL
$8.69 - $14.47 $41,216 - $68,631
-4,743 Reduced 11.98%
34,835 $308,000
Q2 2020

Aug 05, 2020

BUY
$5.21 - $11.03 $206,201 - $436,545
39,578 New
39,578 $422,000
Q4 2018

Feb 05, 2019

SELL
$5.55 - $11.34 $197,585 - $403,715
-35,601 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$9.74 - $12.92 $254,389 - $337,444
-26,118 Reduced 42.32%
35,601 $424,000
Q2 2018

Aug 10, 2018

BUY
$10.16 - $13.65 $627,065 - $842,464
61,719 New
61,719 $630,000

About Syros Pharmaceuticals, Inc.


  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $43.1M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.